Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's Essential Drug Prices Less Severe Than Expected; Some Prices See Increases

This article was originally published in The Pink Sheet Daily

Executive Summary

Prices for half of the drug products on the list will stay at current levels.

You may also be interested in...



China Releases New Regs To Step Up Quality Control For Essential Drugs; Second Part Of EDL Expected In November

SHANGHAI - In the latest effort to strengthen drug safety measures in China, China's State FDA issued Sept. 24 a new quality control regulation for drugs listed on the Essential Drug List. The regulation asks local FDAs to conduct at least two inspections every year of all manufacturing sites for drugs listed

Powerful Chinese Government Commission Set To Issue Price Caps For Essential Drug List Medicines

BEIJING - China's powerful National Development and Reform Commission, which has a virtually unrestricted purview over setting prices for medicines that are included on the country's Essential Drug List, is in the final stages of determining caps for every item on the newly revised list

China's Changing Drug Market In The Wake Of Essential Drugs List

SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel